BIIB Biogen Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
20:03
May 12
May 12
The tweet provides a detailed technical and cross-asset analysis highlighting overbought conditions, defensive rotation, and rising VIX that suggest a cautious or bearish outlook without explicitly stating the author's own directional trade.
12:00
Apr 21
Apr 21
Alzheimer's drugs from Biogen and Lilly are promising.
Anti-amyloid medicines from Biogen and Eli Lilly can break up plaques in the brain and, if given early, could dramatically slow cognitive decline. Data expected later in 2025 may show that early intervention could reduce decline by 40-50% or more.
MED
23:47
Apr 20
Apr 20
Biogen and Gilead are attractive.
Biogen looks attractive after an upgrade highlighting multiple revenue streams including Alzheimer's; Gilead is also liked in the biotech space.
MED
16:27
Feb 26
Feb 26
While Harvard's Allston development is failing, MIT's Kendall Square is described as the "most innovative square mile on the planet" with tenants like Biogen (BIIB) and Google (GOOGL) anchoring the area. In a crashing real estate market (70% vacancy elsewhere), capital and talent flight to quality ("flight to prime"). Companies located in the transit-accessible, thriving Kendall Square ecosystem are signaling resilience and superior positioning compared to competitors in "landlocked" developments. LONG these specific tenants as proxies for the "Quality" factor in the biotech/tech cluster. Broader sector downturns in Biotech or Tech could drag these names down regardless of their office location.
About BIIB Analyst Coverage
Buzzberg tracks BIIB (Biogen Inc.) across 4 sources. 3 bullish vs 0 bearish calls from 3 analysts. Sentiment: predominantly bullish (75%). 4 total trade ideas tracked.